OSOluwatosin SaibuMolecular Simulation

Publications

Publications

14 peer-reviewed papers spanning computational drug discovery, cancer signaling, and molecular modeling (2020-2023).

Protein interactions

2023

Saibu, O. A., Hammed, S. O., Oladipo, O. O., Odunitan, T. T., et al. · Bioorganic & Medicinal Chemistry

Protein-protein interaction and interference of carcinogenesis by supramolecular modifications.

DOI

10.1016/j.bmc.2023.117211

Open DOI

Immunotherapy

2023

Saibu, O. A., Ajayi, T. M., Omoboyowa, D. A., et al. · Arabian Journal of Chemistry

Molecular mechanics and dynamics simulation of CD-47/SIRPα blockade study: a computational study on overcoming immunotherapeutic resistance in pancreatic ductal adenocarcinoma.

DOI

10.1016/j.arabjc.2023.105265

Open DOI

Drug discovery

2023

Saibu, O. A., Singh, G., Omoboyowa, D. A., et al. · Informatics in Medicine Unlocked

Discovery of putative natural compounds inhibitor of the germinant spore receptor CspC in Clostridioides difficile infection: gaining insights via in silico and bioinformatics approach.

DOI

10.1016/j.imu.2023.101339

Open DOI

HER2

2023

Saibu, O. A., Singh, G., Olugbodi, S. A., et al. · Journal of Biomolecular Structure and Dynamics

Identification of HER2 inhibitors from curcumin derivatives using combination of in silico screening and molecular dynamics simulation.

DOI

10.1080/07391102.2023.2175260

Open DOI

Breast cancer

2023

Odunitan, T. T., Saibu, O. A., Apanisile, B. T., et al. · Computers in Biology and Medicine

Integrating biocomputational techniques for breast cancer drug discovery via the HER-2, BCRA, VEGF, and ER protein targets.

DOI

10.1016/j.compbiomed.2023.107737

Open DOI

EGFR

2021

Balogun, T. A., Nureni, I., Olayemi, T. A., ..., Saibu, O. A., et al. · Cancer Informatics

Computational evaluation of bioactive compounds from Colocasia affinis Schott as a novel EGFR inhibitor for cancer treatment.

DOI

10.1177/11769351211049244

Open DOI

HER2

2021

Balogun, T. A., Muhammad, N. I., Saibu, O. A., et al. · Journal of Biomolecular Structure and Dynamics

Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-positive breast cancer: an integrated computational approach.

DOI

10.1080/07391102.2021.1975570

Open DOI

Drug discovery

2021

Balogun, T. A., Oluwasegun, M. I., Alausa, A., ..., Saibu, O. A., et al. · Future Journal of Pharmaceutical Sciences

Receptor tyrosine kinases as a therapeutic target by natural compounds for cancer treatment.

DOI

10.1186/s43094-021-00346-9

Open DOI

Neurodegenerative disease

2021

Omoboyowa, D. A., Balogun, T. A., Omomule, O. M., Saibu, O. A. · Bioinformatics and Biology Insights

Identification of terpenoids from Abrus precatorius against Parkinson's disease proteins using in silico approach.

DOI

10.1177/11779322211050757

Open DOI

SARS-CoV-2

2021

Omoboyowa, D. A., Balogun, T. A., Chukwudozie, O. S., Nweze, V., Saibu, O. A., Alausa, A. · Biointerface Research in Applied Chemistry

SARS-CoV-2 spike glycoprotein as inhibitory target for in silico screening of natural compounds.

DOI

10.33263/briac116.1497414985

Open DOI

Natural products

2021

Omoboyowa, D. A., Joshua, P. E., Nwodo, O. C., Saibu, O. A., et al. · EC Pharmacology and Toxicology

Tithonia diversifolia (Hemsl) A. Gray fractions enhanced anti-plasmodial efficacy of chloroquine in resistant Plasmodium yoelii infected mice.

Natural products

2021

Omoboyowa, D. A., Omomule, O. M., Balogun, T. A., Saibu, O. A., Matibemu, D. S. · Phytomedicine Plus

Protective potential of ethylacetate extract of Abrus precatorius (Linn) seeds against HCl/EtOH-induced gastric ulcer via proinflammatory regulation: in vivo and in silico study.

DOI

10.1016/j.phyplu.2021.100145

Open DOI

Natural products

2020

Omoboyowa, D. A., Balogun, T. A., Saibu, O. A. · J. Comput Sci Syst Biol.

Inhibitory potential of phyto-constituents from sorghum stem on neuro-modulatory enzymes: a computational approach.

Prostate cancer

2021

Omoboyowa, D. A., Balogun, T. A., Saibu, O. A., et al. · Biology, Methods and Protocols

Structure-based discovery of selective CYP17A1 inhibitors for castration-resistant prostate cancer treatment.

DOI

10.1093/biomethods/bpab026

Open DOI